Neogen Chemicals Reports No Deviation in Preferential Issue Fund Utilization

Neogen Chemicals Ltd has submitted its Statement of Deviation & Variation and Monitoring Agency report for the quarter ended June 30, 2026. The report, reviewed by the Audit Committee and monitored by CRISIL Ratings Limited, confirms no deviation or variation in the utilization of funds raised through a preferential issue of equity shares. The total amount raised was ₹161 Crores, allocated to investments in wholly-owned subsidiaries, working capital, and general corporate purposes, all within the disclosed limits. The company has also made this information available on its website and stock exchange portals.